The present application addresses the general problem of antibiotic resistance, in particular antibiotic-resistant tuberculosis (TB). The long-term goal of this research program is to develop new DNA gyrase inhibitors that are highly effective anti-tuberculosis (TB) agents with susceptible, multidrug-resistant, extensively drug- resistant, and completely drug-resistant forms of the disease. The specific goal of the present application is to develop a novel anti-mutant strategy for identifying lead antibacterial agents that will severely restrict the emergence of resistant mutants and to exploit the strategy to specifically identify anti-mutant gyrase inhibitors that are active against wild-type and quinolone-resistant mutants of M. tuberculosis. The anti-mutant strategy is based on the central hypothesis that new antibiotics having a closed or very narrow mutant selection window will severely restrict the rate at which resistant mutants emerge. Such antibiotics are expected to have increased clinical utility and longevity of use. Preliminary studies show that anti-mutant activity of new gyrase inhibitors does narrow the mutant selection window and restricts the recovery of induced mutants.
Three specific aims have been developed to integrate medicinal chemistry, microbiology, biochemistry and molecular modeling studies into a new anti-mutant strategy and to identify lead structures for development as effective anti-TB agents.
In Aims 1 and 2 we will develop new dione-class and C-7 aryl-quinolone-class agents that are active against wild-type cells, known quinolone-resistant gyrase mutants, and induced mutants generated against progenitor compounds within each class. In a third aim we will exploit two different models for agents binding to gyrase to identify and characterize new types of anti-mutant gyrase inhibitors. The expected outcome of this work is the generation of new lead gyrase inhibitors that exhibit a narrow mutant selection window and severely restrict the recovery of resistant mutants. Successful completion of these studies will provide a general framework for obtaining agents with excellent anti-mutant activity. The framework is expected to apply to many other structural and mechanistic antibiotic classes.

Public Health Relevance

Antibiotic resistance has been recognized for more than a decade as a major threat to public health in the US and elsewhere;patients are now dying from once-treatable infections, and few new compounds are in the drug pipeline. Developing a new approach and new criteria for creating novel antibiotics that will restrict the emergence of resistant bacteria will lead to more effective, longer-lived compounds. Application of the ideas to tuberculosis will be significant because on a global basis tuberculosis kills more people than any other infectious disease and because drug-resistant tuberculosis is growing in prevalence.

National Institute of Health (NIH)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Boyce, Jim P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Schools of Pharmacy
Iowa City
United States
Zip Code
Mustaev, Arkady; Malik, Muhammad; Zhao, Xilin et al. (2014) Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. J Biol Chem 289:12300-12
Aldred, Katie J; Kerns, Robert J; Osheroff, Neil (2014) Mechanism of quinolone action and resistance. Biochemistry 53:1565-74
Aldred, Katie J; Breland, Erin J; McPherson, Sylvia A et al. (2014) Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge. Antimicrob Agents Chemother 58:7182-7
Aldred, Katie J; Breland, Erin J; Vl?ková, Vladislava et al. (2014) Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry 53:5558-67
Fenner, Amanda M; Oppegard, Lisa M; Hiasa, Hiroshi et al. (2013) Selective inhibition of bacterial and human topoisomerases by N-arylacyl O-sulfonated aminoglycoside derivatives. ACS Med Chem Lett 4:470-474
Aldred, Katie J; McPherson, Sylvia A; Turnbough Jr, Charles L et al. (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res 41:4628-39
Aldred, Katie J; McPherson, Sylvia A; Wang, Pengfei et al. (2012) Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry 51:370-81
Malik, Muhammad; Marks, Kevin R; Mustaev, Arkady et al. (2011) Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 55:2335-43
Marks, Kevin R; Malik, Muhammad; Mustaev, Arkady et al. (2011) Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones. Bioorg Med Chem Lett 21:4585-8
Malik, Muhammad; Marks, Kevin R; Schwanz, Heidi A et al. (2010) Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality. Antimicrob Agents Chemother 54:5214-21